Table 3. Cancer Vaccination in Clinical Trials.

Cancer	Antigen	Vaccine	Results So Far	References
Melanoma	MAGE-A1/3	Tumor DC/Tumor lysate	TR	Salcedo et al., 2005
	MART-1/gp100/tyros	Peptide/low dose GM-CSF	ICO	Markovic et al., 2006
	VACCIMEL	Allogeneic melanoma/BCG	HR p<0.05	Barrio et al., 2006
Breast	1E10 (GM3 ganglioside)	anti-Id Ab	HR/CR p<0.05	Guthmann et al., 2006
	Membrane Ags	DC/Tumor	SD/DR/TCR	Avigan et al., 2004
	HER2/neu	HER2/neupeptide/DC	SD/TCR	Dees te al., 2004
	HER2/neuE75	Peptide/GM-CSF	RR p<0.19/PSIR	Peoples et al., 2005
	P53	Peptide/DC	SD/TCR	Svane et al., 2004
Cervix Carcinoma	HPV-16L1	polypeptide/VLP	CP up to 48 months	Mao et al., 2006
Pancreas	Survivin	Peptide/Adjuvant	RM/IR (case report)	Wobser et al., 2006
Renal Carcinoma	RNA Tumor	RNA transf DC/depl Tregs	TSTCR p<0.05	Dannull et al., 2005
Prostate Cancer	PSA	Peptide/GM-CSF	PSA-spec TCR	Perambakam et al., 2006
Follicular Lymphoma	Id epitope	Protein	DFS/HR/CR	Inoges et al., 2006

Ab= antibody, CP=complete prevention, BCG=Bacillus Calmette Guerin, CR=cellular responses, DC=dendritic cells, DFS=disease free survival, DR=disease regression, GM-CSF=granulocyte macrophage-colony stimulating factor, PSA=prostate specific antigen, HR=humoral responses, ICO=improved clinical outcome, Id=idiotypic, IR=immune responses, PSA=prostate specific antigen, PSIR=peptide specific immune responses, RM=regression metastases, RR= recurrence reduced, SD= stable disease, TCR=T cell responses, TR=tumor regression, T_regs=regulatory T cells, TSTCR=tumor-specific T cell responses, VLP= virus-like particle.